XML 13 R7.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Secondary Offering
At-the-Market Offering
Common Shares
Common Shares
Secondary Offering
Common Shares
At-the-Market Offering
Treasury Stock
Treasury Stock
Secondary Offering
Capital in Excess of Par Value
Capital in Excess of Par Value
Secondary Offering
 [2]
Capital in Excess of Par Value
At-the-Market Offering
 [2]
Accumulated Other Comprehensive Income/(Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023 [1]       12,757,984                  
Beginning balance at Dec. 31, 2023 $ 130,987     $ 1 [1]         $ 3,608,155 [1]     $ 80 $ (3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares issued under equity compensation plans (in shares) [1]       35,131                  
Shares issued under equity compensation plans 3               3 [1]        
Stock-based compensation 6,000               6,000 [1]        
Repurchase of common stock from Bristol-Myers Squibb (in shares) [1]       (552,307)     552,307            
Repurchase of common stock from Bristol-Myers Squibb (3,000)           $ (3,000)            
Issuance of prefunded warrant 30,000               30,000 [1]        
Comprehensive income (loss) (37,285)                     (483) (36,802)
Ending balance (in shares) at Mar. 31, 2024 [1]       12,240,808                  
Ending balance at Mar. 31, 2024 126,705     $ 1 [1]     $ (3,000)   3,644,158 [1]     (403) (3,514,051)
Ending balance (in shares) at Mar. 31, 2024 [1]             552,307            
Beginning balance (in shares) at Dec. 31, 2023 [1]       12,757,984                  
Beginning balance at Dec. 31, 2023 130,987     $ 1 [1]         3,608,155 [1]     80 (3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Comprehensive income (loss) (125,947)                        
Ending balance (in shares) at Sep. 30, 2024 [1]       12,296,312                  
Ending balance at Sep. 30, 2024 48,884     $ 1 [1]     $ (3,000)   3,654,999 [1]     355 (3,603,471)
Ending balance (in shares) at Sep. 30, 2024 [1]             552,307            
Beginning balance (in shares) at Mar. 31, 2024 [1]       12,240,808                  
Beginning balance at Mar. 31, 2024 126,705     $ 1 [1]     $ (3,000)   3,644,158 [1]     (403) (3,514,051)
Beginning balance (in shares) at Mar. 31, 2024 [1]             552,307            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares issued under equity compensation plans (in shares) [1]       29,095                  
Shares issued under equity compensation plans 19               19 [1]        
Stock-based compensation 5,418               5,418 [1]        
Comprehensive income (loss) (52,454)                     (91) (52,363)
Ending balance (in shares) at Jun. 30, 2024 [1]       12,269,903                  
Ending balance at Jun. 30, 2024 79,688     $ 1 [1]     $ (3,000)   3,649,595 [1]     (494) (3,566,414)
Ending balance (in shares) at Jun. 30, 2024 [1]             552,307            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares issued under equity compensation plans (in shares) [1]       26,409                  
Shares issued under equity compensation plans 13               13 [1]        
Stock-based compensation 5,391               5,391 [1]        
Comprehensive income (loss) (36,208)                     849 (37,057)
Ending balance (in shares) at Sep. 30, 2024 [1]       12,296,312                  
Ending balance at Sep. 30, 2024 $ 48,884     $ 1 [1]     $ (3,000)   3,654,999 [1]     355 (3,603,471)
Ending balance (in shares) at Sep. 30, 2024 [1]             552,307            
Beginning balance (in shares) at Dec. 31, 2024 12,385,001     12,385,001 [2]                  
Beginning balance at Dec. 31, 2024 $ 60,737 [3]     $ 1 [2]     $ (3,000)   3,659,885 [2]     61 (3,596,210)
Beginning balance (in shares) at Dec. 31, 2024 552,307           552,307 [2]            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares issued under equity compensation plans (in shares) [2]       21,709                  
Shares issued under equity compensation plans $ 7               7 [2]        
Stock-based compensation 3,898               3,898 [2]        
Comprehensive income (loss) (50,904)                     (22) (50,882)
Ending balance (in shares) at Mar. 31, 2025 [2]       12,406,710                  
Ending balance at Mar. 31, 2025 $ 13,738     $ 1 [2]     $ (3,000)   3,663,790 [2]     39 (3,647,092)
Ending balance (in shares) at Mar. 31, 2025 [2]             552,307            
Beginning balance (in shares) at Dec. 31, 2024 12,385,001     12,385,001 [2]                  
Beginning balance at Dec. 31, 2024 $ 60,737 [3]     $ 1 [2]     $ (3,000)   3,659,885 [2]     61 (3,596,210)
Beginning balance (in shares) at Dec. 31, 2024 552,307           552,307 [2]            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Comprehensive income (loss) $ (128,002)                        
Ending balance (in shares) at Sep. 30, 2025 19,652,513     19,652,513 [2]                  
Ending balance at Sep. 30, 2025 $ 85,086     $ 2 [2]         3,809,235 [2]     56 (3,724,207)
Ending balance (in shares) at Sep. 30, 2025 0                        
Beginning balance (in shares) at Mar. 31, 2025 [2]       12,406,710                  
Beginning balance at Mar. 31, 2025 $ 13,738     $ 1 [2]     $ (3,000)   3,663,790 [2]     39 (3,647,092)
Beginning balance (in shares) at Mar. 31, 2025 [2]             552,307            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares issued under equity compensation plans (in shares) [2]       50,542                  
Shares issued under equity compensation plans 211               211 [2]        
Stock-based compensation 3,486               3,486 [2]        
Comprehensive income (loss) (41,646)                     (53) (41,593)
Ending balance (in shares) at Jun. 30, 2025 [2]       12,457,252                  
Ending balance at Jun. 30, 2025 (24,211)     $ 1 [2]     $ (3,000)   3,667,487 [2]     (14) (3,688,685)
Ending balance (in shares) at Jun. 30, 2025 [2]             552,307            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares issued under equity compensation plans (in shares) [2]       34,778                  
Shares issued under equity compensation plans 236               236 [2]        
Stock-based compensation 3,072               3,072 [2]        
Shares issued under offering, net of underwriting discounts and offering costs (in shares) [2]         4,893,618 600,198   (552,307)          
Shares issued under offering, net of underwriting discounts and offering costs   $ 107,160 $ 34,279   $ 1 [2]     $ 3,000   $ 104,159 $ 34,279    
Shares issued under prefunded warrant exercise (in shares) [2]       1,666,667                  
Issuance of prefunded warrant 2               2 [2]        
Comprehensive income (loss) $ (35,452)                     70 (35,522)
Ending balance (in shares) at Sep. 30, 2025 19,652,513     19,652,513 [2]                  
Ending balance at Sep. 30, 2025 $ 85,086     $ 2 [2]         $ 3,809,235 [2]     $ 56 $ (3,724,207)
Ending balance (in shares) at Sep. 30, 2025 0                        
[1] All share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).
[2] All share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).
[3] All share and per share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).